Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Emergency Medical Handling in BE Units – V 2.0

Posted on By

BA-BE Studies: SOP for Emergency Medical Handling in BE Units – V 2.0

Standard Operating Procedure for Emergency Medical Handling in BE Units

Department BA-BE Studies
SOP No. SOP/BA-BE/092/2025
Supersedes SOP/BA-BE/092/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To outline a clear and systematic approach for identifying, responding to, and managing medical emergencies that occur in Bioequivalence (BE) units during the conduct of BA/BE studies, ensuring subject safety, prompt medical intervention, and documentation in compliance with ethical and regulatory standards.

2. Scope

This SOP applies to all clinical staff, physicians, nurses, and emergency responders involved in BA/BE studies at clinical research facilities

equipped with BE units.

3. Responsibilities

  • Study Physician: Leads emergency response and determines clinical management.
  • Clinical Research Coordinator (CRC): Assists physician, maintains documentation, and communicates with relevant stakeholders.
  • Nursing Staff: Provides immediate care, administers first aid or emergency drugs as instructed.
  • QA Officer: Ensures all events are documented and reported appropriately.
See also  BA-BE Studies: SOP for Emergency Exit and Fire Drill Plan at Clinical Site - V 2.0

4. Accountability

The Principal Investigator (PI) is accountable for overseeing the implementation of emergency procedures, post-event follow-up, and compliance with reporting obligations to regulatory authorities and Ethics Committees.

5. Procedure

5.1 Preparedness and Infrastructure

  1. Ensure availability of:
    • Emergency crash cart with life-saving medications
    • Functional oxygen cylinders and defibrillator
    • First aid kit and IV infusion sets
  2. Check emergency equipment daily and log in Annexure-1: Emergency Equipment Checklist.
  3. Display emergency contact numbers and local hospital details in BE unit premises.

5.2 Identification of Medical Emergency

  1. Medical emergencies may include:
    • Severe allergic reactions (e.g., anaphylaxis)
    • Chest pain, convulsions, fainting
    • Uncontrolled vomiting, abnormal vitals, or unconsciousness
  2. Any staff member identifying a potential emergency must immediately alert the physician and activate the emergency response system.

5.3 Initial Emergency Response

  1. Physician to assess and initiate emergency care:
    • Administer medication as per medical need
    • Ensure airway, breathing, and circulation (ABCs)
    • Monitor vitals continuously
  2. Record observations in Annexure-2: Emergency Medical Handling Record.
See also  BA-BE Studies: SOP for Risk Assessment of Study Protocol in BA/BE Studies - V 2.0

5.4 External Referral and Hospitalization

  1. If required, transfer subject to the designated hospital:
    • Use ambulance service
    • Send all relevant documents including study protocol, informed consent, and vitals chart
  2. Update sponsor, Ethics Committee, and regulatory body as per reporting timelines.

5.5 Documentation and Reporting

  1. Document complete chronology of the event in:
    • Annexure-2: Emergency Medical Handling Record
    • Annexure-3: Serious Adverse Event (SAE) Form (if applicable)
  2. Report SAEs within 24 hours to Ethics Committee and sponsor.

5.6 Follow-up and Root Cause Analysis

  1. Conduct medical follow-up until resolution or stabilization.
  2. Perform Root Cause Analysis (RCA) and document in Annexure-4: Emergency Event Investigation Form.
  3. Implement corrective and preventive actions as required.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • PI: Principal Investigator
  • SAE: Serious Adverse Event
  • RCA: Root Cause Analysis

7. Documents

  1. Emergency Equipment Checklist – Annexure-1
  2. Emergency Medical Handling Record – Annexure-2
  3. SAE Form – Annexure-3
  4. Emergency Event Investigation Form – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Indian GCP Guidelines
  • Schedule Y – Drugs & Cosmetics Rules
See also  BA-BE Studies: SOP for Volunteer Compensation and Reimbursement - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Emergency Equipment Checklist

Date Item Status Checked By
17/04/2025 Oxygen Cylinder Available Ravi Nair

Annexure-2: Emergency Medical Handling Record

Subject ID Date Event Description Actions Taken Outcome Handled By
VOL-092 17/04/2025 Severe nausea post-dose IV antiemetic administered Resolved Dr. A. Shah

Annexure-3: SAE Form

Subject ID Event Onset Date Reported To Initial Report Date
VOL-092 Severe Vomiting 17/04/2025 EC/Sponsor 17/04/2025

Annexure-4: Emergency Event Investigation Form

Event Root Cause Corrective Action Preventive Action Verified By
Unconsciousness Drug sensitivity Withheld further dose Pre-dose allergy screening QA Officer

Revision History:

Revision Date Revision No. Details Reason Approved By
14/01/2022 1.0 Initial SOP Release Safety Process QA Head
17/04/2025 2.0 Added structured forms and referral procedures Regulatory Compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Analytical Method Development: Analytical Control Strategy Development – V 2.0
Next Post: API Manufacturing: SOP for Blending of Final Dried API – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version